Bluejay Diagnostics Valuation
| BJDX Stock | USD 2.67 0.05 1.84% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Bluejay Diagnostics shows a prevailing Real Value of $2.56 per share. The current price of the firm is $2.67. Our model approximates the value of Bluejay Diagnostics from analyzing the firm fundamentals such as Shares Owned By Insiders of 11.23 %, return on equity of -1.26, and Current Valuation of (1.01 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bluejay Diagnostics' valuation include:
Overvalued
Today
Please note that Bluejay Diagnostics' price fluctuation is dangerous at this time. Calculation of the real value of Bluejay Diagnostics is based on 3 months time horizon. Increasing Bluejay Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bluejay Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bluejay Stock. However, Bluejay Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.67 | Real 2.56 | Hype 2.54 |
The intrinsic value of Bluejay Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bluejay Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bluejay Diagnostics helps investors to forecast how Bluejay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bluejay Diagnostics more accurately as focusing exclusively on Bluejay Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bluejay Diagnostics' intrinsic value based on its ongoing forecasts of Bluejay Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bluejay Diagnostics' closest peers.
Bluejay Diagnostics Cash |
|
Bluejay Diagnostics Total Value Analysis
Bluejay Diagnostics is currently forecasted to have valuation of (1.01 M) with market capitalization of 1.93 M, debt of 222.25 K, and cash on hands of 15.34 M. The negative valuation of Bluejay Diagnostics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Bluejay Diagnostics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.01 M) | 1.93 M | 222.25 K | 15.34 M |
Bluejay Diagnostics Asset Utilization
One of the ways to look at asset utilization of Bluejay is to check how much profit was generated for every dollar of assets it reports. Bluejay Diagnostics shows a negative utilization of assets of -0.66 percent, losing $0.006584 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bluejay Diagnostics shows how discouraging it operates for each dollar spent on its assets.Bluejay Diagnostics Profitability Analysis
Based on Bluejay Diagnostics' profitability indicators, Bluejay Diagnostics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Bluejay Diagnostics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -2 M | Current Value -1.6 M | Quarterly Volatility 896.2 K |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.16 | 0.18 |
|
|
For Bluejay Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bluejay Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bluejay Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bluejay Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bluejay Diagnostics over time as well as its relative position and ranking within its peers.
Bluejay Diagnostics Earnings per Share Projection vs Actual
The next projected EPS of Bluejay Diagnostics is estimated to be 0.0 with future projections ranging from a low of 0.0 to a high of 0.0. Bluejay Diagnostics' most recent 12-month trailing earnings per share (EPS TTM) is at 657.48. Please be aware that the consensus of earnings estimates for Bluejay Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.Bluejay Diagnostics Earnings Estimation Breakdown
The calculation of Bluejay Diagnostics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Bluejay Diagnostics is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Bluejay Diagnostics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Bluejay Diagnostics Earnings Projection Consensus
Suppose the current estimates of Bluejay Diagnostics' value are higher than the current market price of the Bluejay Diagnostics stock. In this case, investors may conclude that Bluejay Diagnostics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Bluejay Diagnostics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 0 | 19.5% | -27.81 | 0.0 | 657.48 |
Bluejay Diagnostics Ownership Allocation
Bluejay Diagnostics shows 11.23 percent of its outstanding shares held by insiders and 3.03 percent owned by other corporate entities.Bluejay Diagnostics Profitability Analysis
Net Loss for the year was (7.72 M) with profit before overhead, payroll, taxes, and interest of 48.91 K.About Bluejay Diagnostics Valuation
Our relative valuation model uses a comparative analysis of Bluejay Diagnostics. We calculate exposure to Bluejay Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bluejay Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -179.2 K | -188.1 K | |
| Pretax Profit Margin | (33.60) | (35.28) | |
| Operating Profit Margin | (33.67) | (35.36) | |
| Net Loss | (33.60) | (35.28) | |
| Gross Profit Margin | 0.18 | 0.16 |
Bluejay Diagnostics Current Valuation Indicators
Valuation refers to the process of determining the present value of Bluejay Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bluejay we look at many different elements of the entity such as Bluejay's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bluejay Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bluejay Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bluejay Diagnostics' worth.Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.